carbamates has been researched along with Arteriosclerosis, Coronary in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, CF | 1 |
| Dai, CY | 1 |
| Yeh, ML | 1 |
| Huang, CI | 1 |
| Lee, HC | 1 |
| Lai, WT | 1 |
| Liang, PC | 1 |
| Lin, YH | 1 |
| Hsieh, MY | 1 |
| Hou, NJ | 1 |
| Lin, ZY | 1 |
| Chen, SC | 1 |
| Huang, JF | 1 |
| Chuang, WL | 1 |
| Yu, ML | 1 |
| Ferrannini, E | 1 |
| DeFronzo, RA | 1 |
| Rahmi, RM | 1 |
| Uchida, AH | 1 |
| Rezende, PC | 1 |
| Lima, EG | 1 |
| Garzillo, CL | 1 |
| Favarato, D | 1 |
| Strunz, CM | 1 |
| Takiuti, M | 1 |
| Girardi, P | 1 |
| Hueb, W | 1 |
| Kalil Filho, R | 1 |
| Ramires, JA | 1 |
| Wang, Z | 1 |
| Nicholls, SJ | 1 |
| Rodriguez, ER | 1 |
| Kummu, O | 1 |
| Hörkkö, S | 1 |
| Barnard, J | 1 |
| Reynolds, WF | 1 |
| Topol, EJ | 1 |
| DiDonato, JA | 1 |
| Hazen, SL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Follow-up of Anti-Carbamylated Antibody Status in Rheumatoid Arthritis Patients at 6, 12 and 18 Months[NCT02958319] | 278 participants (Actual) | Observational | 2016-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To explore the clinical differences in activity indexes (DAS28-ESR) at 6, 12 and 18 months of follow-up according the anti-CarP status.~The DAS28 is a composite score derived from 4 measures, one of them can be the erythrocyte sedimentation rate (ESR). We will be using the DAS28-ESR version. To calculate the DAS28-ESR the rheumatologist or specialist nurse will:- count the number of swollen joints (out of the 28), count the number of tender joints (out of the 28), take blood to measure ESR, ask participants to make a 'global assessment of health' (indicated by marking a 10 cm line between very good and very bad).~DAS28-ESR is calculated with classic calculators and resulting values are interpreted as follows:~<2.6: disease remission 2.6 - 3.2: low disease activity 3.2 - 5.1: moderate disease activity >5.1: high disease activity" (NCT02958319)
Timeframe: 6, 12 and 18 Months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 6 MONTHS | 12 MONTHS | 18 MONTHS | |
| Anti P Carb Negative RA Patients | 3.75 | 3.59 | 3.65 |
| Anti P Carb Positive RA Patients | 3.72 | 3.69 | 3.77 |
1 review available for carbamates and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Topics: Carbamates; Clinical Trials as Topic; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus, Type | 2015 |
3 other studies available for carbamates and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
Topics: Aged; Antiviral Agents; Carbamates; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dys | 2020 |
Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease.
Topics: Adamantane; Aged; Carbamates; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hy | 2013 |
Protein carbamylation links inflammation, smoking, uremia and atherogenesis.
Topics: Animals; Atherosclerosis; Blood Proteins; Carbamates; Cholesterol; Citrulline; Clinical Trials as To | 2007 |